OLEMA
19 Apr 2022
OLEMA
NCT04505826
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
Olema Pharmaceuticals, Inc.
Cancer Type | Breast |
---|---|
Trial Type | Treatment |
Phase | Phase I; Phase II |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
Anticipated Start Date | 2020-08-13 |
Anticipated End Date | 2023-12-01 |
Hospital | Cancer Research SA |
---|---|
Clinical Trial Coordinator | Kelly Mead |
admin@cancerresearchsa.com.au | |
Phone | 08 8359 2565 |
Principal Investigator | Dr Meena Okera |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs